Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

Festi D; Schiumerini R; Scaioli E; Colecchia A

doi:10.1111/apt.12228

Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

Festi D, Schiumerini R, Scaioli E, Colecchia A

MeSH — NLM indexing Fatty Liver / diagnosis Humans

Acciones del personal

Descargar PDF

Los archivos son para uso autorizado únicamente en los canales asociados de BioPredictive.

Fibrotest Actitest Letter Independent Group Italy

Autores (4)

Cita

Festi D, Schiumerini R, Scaioli E, Colecchia A. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply. Aliment Pharmacol Ther. 2013;37(6):656-7. doi:10.1111/apt.12228.

Identificadores

DOI: 10.1111/apt.12228
PMID: 23406410

Pruebas

Enfermedades hepáticas

Lesiones hepáticas

Temas

Región

Carrito

Su carrito está vacío.

Explore las publicaciones y use Añadir al carrito en cualquier página de detalle para crear un archivo ZIP que pueda enviar a los clientes.

Explorar las publicaciones

Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

Más de Festi D

Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

Más sobre el mismo tema

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Noninvasive Assessment of Liver Fibrosis.

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).